Possible nitric oxide modulation in protective effects of Withaferin A against stress induced neurobehavioural changes

Journal of Medicinal Plants Research

Volumn 4, Issue 6, 2010, Pages 490-495

  Khan, Zaved Ahmed ^a   Ghosh, Asit Ranjan ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Anxiety; L NAME; nNOS; Withaferin A

Indexed keywords

DIAZEPAM; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; WITHAFERIN A; WITHANIA SOMNIFERA EXTRACT;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; IMMOBILIZATION STRESS; MALE; MAZE TEST; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; RAT; TRANQUILIZING ACTIVITY; WISTAR RAT; WITHANIA SOMNIFERA;

RATTUS; WITHANIA SOMNIFERA;

EID: 77951469782     PISSN: 19960875     EISSN: 19960875     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ballinger BR (1990). Hypnotics and anxiolytics. Br. Med. J. 300: 456-458.
2. Beaubrun G, Gray GE (2000). A review of herbal medicines for psychiatric disorders. Psychiatr. Serv. 51:1130-1134.
3. Bhatnagar M, Sisodia SS, Bhatnagar R (2005). Antiulcer and antioxidant activity of Asparagus racemosus WIILD and Withania somnifera DUNN in Rats. Ann N Y Acad. Sci. 1056: 261-278.
4. Bhattacharya SK, Satyan KS (1997). Experimental methods for the evaluation of psychotropic agents. Indian J. Exp. Biol. 35: 565-575.
5. Bohus B, Koolhas JM, Korte M, Bouws GAH, Eisenga W, Smit J (1990). Behavioral physiology of serotonergic and steroid like anxiolytics as anti-stress drugs. Neurosci. Biobehav. Rev. 14: 529-534.
6. Bone K (1996). Clinical applications of ayurvedic and Chinese herbs. Monographs for the western herbal practitioners. Phytotherapy Press, Australia pp. 137-141.
7. Carli M, Prontera C, Samanin R (1989). Effects of 5HT1A agonist in stress induced deficit in the open field locomotor activity of rats, evidence that this model identifies anxiolytic activity. Neuropharmacol. 28: 471-476.
8. Elsakka M, Grigorescu E, Stanescu U (1990). New data referring to chemistry of Withania somnifera species. Rev. Med. Chir. Soc. Med. Nat. Iasi. 94(2): 385-387.
9. Gairthwaite J, Charles SL, Chess (1998). Endothelium derived relaxing factor release on the activation of NMDA receptor suggests role as intracellular messenger in the brain. Nature 336: 385-388.
10. Ganzera M, Choudhary MI, Khan IA (2003). Quantitative HPLC analysis of withanolides in Withania somnifera. Fitoterapia 74(1-2): 68-76.
11. Gupta SK, Dua A, Vohra BP (2003). Withania somnifera (Ashwagandha) attenuates antioxidant defense in aged spinal cord and inhibits copper induced lipid peroxidation and protein oxidative modifications. Drug Metabol. Drug Interact. 19: 211-222.
12. Gupta GL, Rana AC (2007). Withania somnifera (Ashwagandha): a review. Pharmacogn Rev. 1: 129-136.
13. Holm M (1988). Prescription of benzodiazepines in general practice in the county of Arhus, Denmark. Dan. Med. Bull. 35: 495-499.
14. Lader MH (1999). Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?. Eur. Neuropsychopharmacol. 9 Suppl. 6: 399-405.
15. Lake J (2000). Psychotropic medications from natural products: a review of promising research and recommendations. Altern. Ther. Health Med. 6: 6-45.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275.
17. Mishra LC, Singh BB, Dagenais S (2000). Scientific basis for therapeutic use of Withania somnifera (ashwagandha): A review. Altern. Med. Rev. 5: 334-346.
18. Moncada S, Palmer RMG, Higgs EA (1991). Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:109-142.
19. Oh JH, Lee TJ, Park JW, Kwon TK (2008). Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-B in RAW 264.7 cells. Eur. J. Pharmacol. 599(1-3): 11-17.
20. Pellow S, Chopin SE, File SE, Briley M (1985). Validation of open closed arm entries in an elevated plus maze as a measure of anxiety in the rat. J. Neurosci. Methods 14: 140-167.
21. Rang HP, Dale MM, Ritter JM (1995). Pharmacology (third ed.), Churchill Livingstone, Edinburgh pp. 160-200.
22. Selye H (1936). A syndrome produced by diversal nocuous agents. Nature 13: 32.
23. Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M (2001). Elevated plasma nitrate levels in depressive states. J. Affect. Disord. 63(1-3): 221-224.
24. Tracey WR, Tse J, Carter G (1995). Lipopolysaccharide induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J. Pharmacol. Exp. Ther. 282: 1011-1015.
25. Zhang J, Snyder SH (1995). Nitric oxide in the nervous system. Annu. Rev. Pharmacol. Toxicol. 35: 213-233.